BIOSTEM TECHNOLOGIES NEW - BSEM STOCK NEWS

BioStem Technologies Inc. (OTC: BSEM) will report its first quarter 2024 financial results on Tuesday, May 14, 2024. The leading biotechnology company specializes in placental derived allografts for advanced wound care. A conference call and webcast discussing the financial results and corporate updates will be held at 4:30 pm ET on the same day.

BioStem Technologies Inc. (OTC: BSEM) has been granted Prioritized Examination by the USPTO for its patent application on STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. This patent protects BioStem's method of processing human amniotic tissue, important for wound care treatment. The global wound care dressing market is projected to grow at a CAGR of 4.16% from 2024 to 2030.

BioStem Technologies Inc. (OTC: BSEM) has hired Nick McCoy to lead the Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials for their BioREtain Allografts. These trials aim to meet the evolving reimbursement landscape requirements and ensure patient access to their products. McCoy's extensive experience in clinical research will help accelerate the completion of trials and demonstrate the real-world benefits of BioStem's products.

BioStem Technologies Inc. (OTC: BSEM) CEO, Jason Matuszewski, will present at the 2024 Planet MicroCap Showcase in Vegas. The company focuses on placental derived biologics for advanced wound care. The event aims to discuss the company's growth strategy for 2024.

BioStem Technologies Inc. has completed a two-year audit, positioning itself for an uplisting to a senior stock exchange. The successful audit enhances transparency and regulatory compliance, showcasing robust revenue growth in 2023.

BioStem Technologies Inc. CEO, Jason Matuszewski, will present at the LD Micro Invitational Conference to discuss the company's growth in 2023 and future plans for 2024, including the successful launch of Amniowrap2™. The conference will feature presentations from 80 companies with one-on-one meeting opportunities.

BioStem Technologies Inc. (BSEM) reported exceptional financial results for the fourth quarter and full year 2023, with revenue reaching $11.5 million, a 1,355% year-over-year growth. The successful commercial launch of AmnioWrap2 drove this growth, leading to a gross margin of 95% and an Adjusted EBITDA income of $1.67 million in the fourth quarter. The company also highlighted key operational achievements, including acquisitions, clinical trials initiation, and product portfolio expansion. Despite increased operating expenses, BioStem projects strong growth in 2024.

BioStem Technologies Inc. (BSEM) will release its fourth quarter 2023 financial results on April 1st, 2024. The company, specializing in regenerative medicine, will host a conference call to discuss the financial results and provide a corporate update.

BioStem Technologies Inc. (OTC: BSEM) reports a significant increase in net revenues for the fourth quarter of 2023, reaching $11.5 million, and for the full year, reaching $16.7 million. The company highlights the successful launch and widespread acceptance of Amniowrap2™, its innovative placental-derived allograft product. BioStem also announces key operational updates, including commercialization agreements and government contract listings. Recent achievements include the appointment of a new Chief Commercial Officer and the establishment of national pricing for AmnioWrap2TM. The company plans to discuss its financial results in a conference call scheduled for March 2024.